TransCode Therapeutics Investor Relations Material
Latest events
AGM 2025
TransCode Therapeutics
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from TransCode Therapeutics Inc
Access all reports
TransCode Therapeutics Inc. is a U.S.-based biotechnology company focused on developing RNA-targeted therapies for treating cancer. The company uses its proprietary TTX platform to design and deliver RNA-based therapeutics aimed at addressing previously undruggable cancer targets. TransCode’s research primarily involves preclinical and clinical development of treatments for metastatic and solid tumors, aiming to improve precision and efficacy in cancer treatment. The company is headquartered in Boston, Massachusetts, and its shares are listed on the NASDAQ.
Latest articles
)
Lowe's Companies: Building a One-Stop Shop for Home Improvement
Lowe's Companies began as a single store in 1921 and has steadily expanded its footprint and offerings, now operating 1,750 stores across the U.S.
7 May 2025
)
Greg Abel: Succeeding Warren Buffett at Berkshire Hathaway
After decades working with Warren Buffett and Charlie Munger, Greg Abel was named Buffett’s successor as he steps down in late 2025.
5 May 2025
)
Intuitive Surgical: Enhancing Surgery with Robotic Precision
Intuitive Surgical has revolutionized surgery with robotics, building its dominant position through decades of innovation, validation, and expansion.
2 May 2025
Ticker symbol
RNAZ
Country
🇺🇸 United States